European expert opinion on the management of invasive candidiasis in adults

Clinical Microbiology and Infection

Volumn 17, Issue SUPPL. 5, 2011, Pages 1-12

  Kullberg, B J ^a   Verweij, P E ^a   Akova, M ^b   Arendrup, M C ^c   Bille, J ^d   Calandra, T ^d   Cuenca Estrella, M ^e   Herbrecht, R ^f   Jacobs, F ^g   Kalin, M ^h   Kibbler, C C ⁱ   Lortholary, O ^j,k   Martino, P ^l   Meis, J F ^m   Munoz P ⁿ   Odds, F C ^o   De Pauw, B E ^a   Rex, J H ^p,q   Roilides, E ^r   Rogers, T R ^s   Ruhnke, M ^t   Ullmann, A J ^u   Uzun, O ^b   Vandewoude, K ^v   Vincent, J L ^g   Donnelly, J P ^a   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HACETTEPE UNIVERSITY   (Turkey)

^c STATENS SERUM INSTITUT   (Denmark)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g ERASME HOSPITAL   (Belgium)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

^j INSTITUT PASTEUR   (France)

^k UNIVERSITÉ PARIS DESCARTES   (France)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m CANISIUS WILHELMINA HOSPITAL   (Netherlands)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o UNIVERSITY OF ABERDEEN   (United Kingdom)

^p ASTRAZENECA   (United Kingdom)

^q UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^r ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^s TRINITY COLLEGE DUBLIN   (Ireland)

^t HUMBOLDT UNIVERSITY   (Germany)

^u JOHANNES GUTENBERG UNIVERSITY   (Germany)

^v GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Candida; Candidaemia; Consensus; Guidelines; Therapy

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; DRUG; ECHINOCANDIN; EFUNGUMAB; FLUCONAZOLE; FLUCYTOSINE; HEAT SHOCK PROTEIN 90; ITRACONAZOLE; MICAFUNGIN; PYRROLE DERIVATIVE; VORICONAZOLE;

ABNORMAL LABORATORY RESULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASSAY; AUTOPSY; BLOOD CULTURE; CANCER PATIENT; CANDIDA; CANDIDA ALBICANS; CANDIDA ENDOCARDITIS; CANDIDA ENDOPHTHALMITIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDEMIA; CANDIDIASIS; CATHETER INFECTION; CATHETER REMOVAL; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CENTRAL NERVOUS SYSTEM INFECTION; CHORIORETINITIS; CONSENSUS DEVELOPMENT; CRITICALLY ILL PATIENT; CRYPTOCOCCUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG PENETRATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EUROPE; FEBRILE NEUTROPENIA; FOLLOW UP; FUNGAL COLONIZATION; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNOTHERAPY; INCIDENCE; INDWELLING CATHETER; INFECTION PREVENTION; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER TUMOR; MEDICAL DECISION MAKING; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; NONHUMAN; OPHTHALMOSCOPY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA EXAMINATION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THERAPY DELAY; TREATMENT OUTCOME; TREATMENT RESPONSE; TRICHOSPORON; UNSPECIFIED SIDE EFFECT;

CANDIDA;

EID: 80052220833     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03615.x     Document Type: Article

References (71)

1. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-643.
2. Marchetti O, Bille J, Fluckiger U et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-320.
3. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-322.
4. Guery BP, Arendrup MC, Auzinger G et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part i. Epidemiology and diagnosis. Intensive Care Med 2009; 35: 55-62.
5. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-1442.
6. Vincent JL, Anaissie E, Bruining H et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24: 206-216.
7. Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008; 14: 487-494.
8. Bassetti M, Righi E, Costa A et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21.
9. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010; 16: 445-452.
10. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-630.
11. Colombo AL, Nucci M, Salomao R et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34: 281-286.
12. Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg 2000; 135: 160-165.
13. Edwards JE Jr, Bodey GP, Bowden RA et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43-59.
14. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645.
15. Kumar A, Ellis P, Arabi Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-1248.
16. Lecciones JA, Lee JW, Navarro EE et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992; 14: 875-883.
17. Kullberg B, Rex J, Ruhnke M, Sobel J, Pappas P. Candidaemia secondary to intravascular catheter colonisation?-authors' reply Lancet 2006; 367: 729.
18. Leroy O, Gangneux JP, Montravers P et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37: 1612-1618.
19. Leroy O, Mira JP, Montravers P, Gangneux JP, Lortholary O. Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care 2010; 14: R98.
20. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
21. DiNubile MJ, Hille D, Sable CA, Kartsonis NA. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect 2005; 50: 443-449.
22. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482.
23. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phaseIII randomised double-blind trial. Lancet 2007; 369: 1519-1527.
24. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-893.
25. Betts RF, Nucci M, Talwar D et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-1684.
26. Tuil O, Cohen Y. An open comparative multicenter study of intravenous (iv) itraconazole versus iv fluconazole in the treatment of candidemia in non-neutropenic patients. Crit Care 2003; 7 (suppl 2): S63-S64.
27. Vandewoude K, Vogelaers D, Decruyenaere J et al. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 1997; 41: 2714-2718.
28. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
29. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-1228.
30. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22 (suppl 2): S73-S88.
31. Guinea J, Pelaez T, Rodriguez-Creixems M et al. Empirical treatment of candidemia in intensive care units: fluconazole or broad-spectrum antifungal agents? Med Mycol 2009; 47: 515-520.
32. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-771.
33. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
34. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
35. European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on fluconazole. Clin Microbiol Infect 2008; 14: 193-195.
36. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST technical note on voriconazole. Clin Microbiol Infect 2008; 14: 985-987.
37. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42: 938-944.
38. Arendrup MC, Garcia-Effron G, Buzina W et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 2009; 53: 1185-1193.
39. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48: 2373-2380.
40. Arendrup MC, Garcia-Effron G, Lass-Florl C et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST edef 7.1, CLSI m27-a3, Etest, disk diffusion, and agar dilution methods with RPMI and Isosensitest media. Antimicrob Agents Chemother 2010; 54: 426-439.
41. Slater JL, Howard SJ, Sharp A et al. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Chemother 2011; 55: 3075-3083.
42. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturally occurring proline-to-alanine amino acid change in fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 52: 2305-2312.
43. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-4752.
44. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56: 126-129.
45. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis on micafungin. J Clin Microbiol 2010; 48: 2373-2380.
46. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46: 171-179.
47. Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-2645.
48. Pachl J, Svoboda P, Jacobs F et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42: 1404-1413.
49. Herbrecht R, Fohrer C, Nivoix Y. Mycograb for the treatment of invasive candidiasis. Clin Infect Dis 2006; 43: 1083.
50. Pappas P, Andes D, Benjamin D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
51. Oude Lashof AML, Donnelly JP, Meis JFGM, Van der Meer JWM, Kullberg BJ. Duration of antifungal treatment and development of delayed complications in patients with candidemia. Eur J Clin Microbiol Infect Dis 2003; 22: 43-48.
52. Henderson DK, Edwards JE Jr, Montgomeries JZ. Hematogenous Candida endophthalmitis in patients receiving parenteral hyperalimentation fluids. J Infect Dis 1981; 143: 655-661.
53. Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine (Baltimore) 2003; 82: 187-202.
54. Rex JH, Bennett JE, Sugar AM et al. Intravascular catheter exchange and duration of candidemia. Clin Infect Dis 1995; 21: 994-996.
55. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002; 34: 591-599.
56. Nucci M, Anaissie E, Betts RF et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010; 51: 295-303.
57. Walsh TJ, Rex JH. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002; 34: 600-602.
58. Pelz RK, Hendrix CW, Swoboda SM et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-548.
59. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-1717.
60. Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-1072.
61. Rex JH. Antifungal prophylaxis in the intensive care unit: who should get it? Crit Care Med 2006; 34: 1286-1287.
62. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005; 43: 235-243.
63. Schuster MG, Edwards JE Jr, Sobel JD et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008; 149: 83-90.
64. Perez-Parra A, Munoz P, Guinea J, Martin-Rabadan P, Guembe M, Bouza E. Is Candida colonization of central vascular catheters in non-candidemic, non-neutropenic patients an indication for antifungals? Intensive Care Med 2009; 35: 707-712.
65. Leon C, Ruiz-Santana S, Saavedra P et al. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-737.
66. Leon C, Ruiz-Santana S, Saavedra P et al. Usefulness of the 'Candida score' for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 1624-1633.
67. Prella M, Bille J, Pugnale M et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 2005; 51: 95-101.
68. Mitsutake K, Miyazaki T, Tashiro T et al. Enolase antigen, mannan antigen, cand-tec antigen, and beta-glucan in patients with candidemia. J Clin Microbiol 1996; 34: 1918-1921.
69. Sendid B, Poirot JL, Tabouret M et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002; 51: 433-442.
70. Arendrup MC, Bergmann OJ, Larsson L, Nielsen HV, Jarlov JO, Christensson B. Detection of candidaemia in patients with and without underlying haematological disease. Clin Microbiol Infect 2010; 16: 855-862.
71. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1-->3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-659.